Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?

MLA

Moya-Alarcón, Carlota, et al. “Olaparib as First Line in BRCA-Mutated Advanced Ovarian Carcinoma: Is It Cost-Effective in Spain?” Gynecologic Oncology, vol. 164, no. 2, Feb. 2022, pp. 406–14. EBSCOhost, https://doi.org/10.1016/j.ygyno.2021.11.011.

APA

Moya-Alarcón, C., González-Domínguez, A., Ivanova-Markova, Y., Gimeno-Ballester, V., Barretina-Ginesta, M.-P., Pérez-Fidalgo, J. A., & Redondo, A. (2022). Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain? Gynecologic Oncology, 164(2), 406–414. https://doi.org/10.1016/j.ygyno.2021.11.011

Chicago

Moya-Alarcón, Carlota, Almudena González-Domínguez, Yoana Ivanova-Markova, Vicente Gimeno-Ballester, Maria-Pilar Barretina-Ginesta, José Alejandro Pérez-Fidalgo, and Andrés Redondo. 2022. “Olaparib as First Line in BRCA-Mutated Advanced Ovarian Carcinoma: Is It Cost-Effective in Spain?” Gynecologic Oncology 164 (2): 406–14. doi:10.1016/j.ygyno.2021.11.011.